ES2128343T3 - Formulaciones de prostaglandina liposomica. - Google Patents
Formulaciones de prostaglandina liposomica.Info
- Publication number
- ES2128343T3 ES2128343T3 ES92401262T ES92401262T ES2128343T3 ES 2128343 T3 ES2128343 T3 ES 2128343T3 ES 92401262 T ES92401262 T ES 92401262T ES 92401262 T ES92401262 T ES 92401262T ES 2128343 T3 ES2128343 T3 ES 2128343T3
- Authority
- ES
- Spain
- Prior art keywords
- prostaglandine
- vasculitis
- liposomic
- formulations
- adhesion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1277—Preparation processes; Proliposomes
- A61K9/1278—Post-loading, e.g. by ion or pH gradient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Dispersion Chemistry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
SE PRESENTA UN METODO PARA TRATAR EL SINDROME DE ACTIVACION / ADHESION CELULAR EN LOS MAMIFEROS, INCLUYENDO LOS HUMANOS, MEDIANTE LA ADMINISTRACION DE UNA PROSTAGLANDINA ASOCIADA CON UN LIPOSOMA. TALES SINDROMES DE ACTIVACION / ADHESION CELULAR PUEDEN INCLUIR LAS LESIONES DE REPERFUSION, EL SHOCK SEPTICO, EL INFARTO DE MIOCARDIO, EL SINDROME AGOTAMIENTO RESPIRATORIO EN LOS ADULTOS, LA VASCULITIS REUMATOIDE, LA VASCULITIS SISTEMICA, EL SHOCK POSTRAUMATICO, LAS LESIONES POR QUEMADURAS O LA RESTENOSIS POSTERIOR A LA ANGIOPLASTIA. EN UNA CONFORMACION MAS ADECUADA, LA PROSTAGLANDINA ESTA ENCAPSULADA EN LOS LIPOSOMAS.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US69731491A | 1991-05-07 | 1991-05-07 | |
| US87620092A | 1992-04-30 | 1992-04-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2128343T3 true ES2128343T3 (es) | 1999-05-16 |
Family
ID=27105991
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES92401262T Expired - Lifetime ES2128343T3 (es) | 1991-05-07 | 1992-05-06 | Formulaciones de prostaglandina liposomica. |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP0512916B1 (es) |
| JP (1) | JPH06507417A (es) |
| KR (1) | KR100300772B1 (es) |
| AT (1) | ATE176401T1 (es) |
| AU (1) | AU664704B2 (es) |
| CA (1) | CA2108788C (es) |
| DE (1) | DE69228332T2 (es) |
| DK (1) | DK0512916T3 (es) |
| ES (1) | ES2128343T3 (es) |
| FI (1) | FI934913A7 (es) |
| GR (1) | GR3029641T3 (es) |
| IE (1) | IE921461A1 (es) |
| MX (1) | MX9202131A (es) |
| NO (1) | NO306048B1 (es) |
| WO (1) | WO1992019243A1 (es) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5925375A (en) * | 1987-05-22 | 1999-07-20 | The Liposome Company, Inc. | Therapeutic use of multilamellar liposomal prostaglandin formulations |
| US5811118A (en) * | 1987-05-22 | 1998-09-22 | The Liposome Company, Inc. | Methods of treatment using unilamellar liposomal arachidonic acid metabolite formulations |
| US5882678A (en) * | 1990-01-12 | 1999-03-16 | The Liposome Co, Inc. | Interdigitation-fusion liposomes containing arachidonic acid metabolites |
| US5629287A (en) * | 1991-01-18 | 1997-05-13 | University College London | Depot formulations |
| US5610148A (en) * | 1991-01-18 | 1997-03-11 | University College London | Macroscopically oriented cell adhesion protein for wound treatment |
| EP0679088B1 (en) | 1992-09-29 | 2002-07-10 | Inhale Therapeutic Systems | Pulmonary delivery of active fragments of parathyroid hormone |
| US5853755A (en) * | 1993-07-28 | 1998-12-29 | Pharmaderm Laboratories Ltd. | Biphasic multilamellar lipid vesicles |
| CA2175057A1 (en) * | 1993-11-04 | 1995-05-11 | Robert P. Lenk | Multilamellar liposomal arachidonic acid metabolite formulations |
| DE69416425T2 (de) * | 1993-11-16 | 1999-06-10 | The Liposome Co.,Inc., Princeton, N.J. | Arachidonsäuremetaboliten enthaltende interdigitations-fusions-liposomen |
| WO1995018620A1 (en) * | 1994-01-11 | 1995-07-13 | The Liposome Company, Inc. | Treatment using arachidonic acid metabolite and particulate formulations |
| ATE416755T1 (de) | 1994-03-07 | 2008-12-15 | Nektar Therapeutics | Verfahren und zusammensetzung für die pulmonale darreichung von insulin |
| US5718917A (en) * | 1995-12-15 | 1998-02-17 | Harvard Scientific Corporation | PGE-1 containing lyophilized liposomes for use in the treatment of erectile dysfunction |
| US6001333A (en) * | 1997-09-12 | 1999-12-14 | See; Jackie R. | Methods of preparing micro encapsulated agents for use in the detection of tumors by CT imaging |
| US20060165606A1 (en) | 1997-09-29 | 2006-07-27 | Nektar Therapeutics | Pulmonary delivery particles comprising water insoluble or crystalline active agents |
| US6565885B1 (en) | 1997-09-29 | 2003-05-20 | Inhale Therapeutic Systems, Inc. | Methods of spray drying pharmaceutical compositions |
| US6309623B1 (en) | 1997-09-29 | 2001-10-30 | Inhale Therapeutic Systems, Inc. | Stabilized preparations for use in metered dose inhalers |
| US7871598B1 (en) | 2000-05-10 | 2011-01-18 | Novartis Ag | Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use |
| PT1458360E (pt) | 2001-12-19 | 2011-07-13 | Novartis Ag | Derivados de indole como agonistas do recetor s1p1 |
| US8697120B2 (en) | 2006-05-01 | 2014-04-15 | Johns Hopkins University | Method and use of nano-scale devices for reduction of tissue injury in ischemic and reperfusion injury |
| TWI728255B (zh) * | 2017-07-24 | 2021-05-21 | 國邑藥品科技股份有限公司 | 包含弱酸藥物之脂質體組成物及其用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS58222014A (ja) * | 1982-06-18 | 1983-12-23 | Taisho Pharmaceut Co Ltd | プロスタグランジンｅ↓１脂肪乳剤 |
| EP0153858A3 (en) * | 1984-02-29 | 1985-12-11 | The Upjohn Company | The therapeutic use of prostaglandins |
| US4820732A (en) * | 1985-10-04 | 1989-04-11 | The Upjohn Company | Method and compositions for reducing dysfunction in angioplasty procedures |
| US5082664A (en) * | 1987-05-22 | 1992-01-21 | The Liposome Company, Inc. | Prostaglandin-lipid formulations |
-
1992
- 1992-05-06 ES ES92401262T patent/ES2128343T3/es not_active Expired - Lifetime
- 1992-05-06 EP EP92401262A patent/EP0512916B1/en not_active Expired - Lifetime
- 1992-05-06 DK DK92401262T patent/DK0512916T3/da active
- 1992-05-06 AT AT92401262T patent/ATE176401T1/de not_active IP Right Cessation
- 1992-05-06 DE DE69228332T patent/DE69228332T2/de not_active Expired - Fee Related
- 1992-05-07 JP JP4512039A patent/JPH06507417A/ja active Pending
- 1992-05-07 MX MX9202131A patent/MX9202131A/es not_active IP Right Cessation
- 1992-05-07 WO PCT/US1992/003895 patent/WO1992019243A1/en not_active Ceased
- 1992-05-07 AU AU20273/92A patent/AU664704B2/en not_active Ceased
- 1992-05-07 FI FI934913A patent/FI934913A7/fi not_active Application Discontinuation
- 1992-05-07 KR KR1019930703258A patent/KR100300772B1/ko not_active Expired - Fee Related
- 1992-05-07 CA CA002108788A patent/CA2108788C/en not_active Expired - Fee Related
- 1992-07-01 IE IE146192A patent/IE921461A1/en not_active IP Right Cessation
-
1993
- 1993-11-05 NO NO934016A patent/NO306048B1/no unknown
-
1999
- 1999-03-09 GR GR990400732T patent/GR3029641T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE69228332T2 (de) | 1999-09-16 |
| GR3029641T3 (en) | 1999-06-30 |
| EP0512916A3 (en) | 1992-12-09 |
| ATE176401T1 (de) | 1999-02-15 |
| FI934913L (fi) | 1993-11-05 |
| AU664704B2 (en) | 1995-11-30 |
| DE69228332D1 (de) | 1999-03-18 |
| FI934913A0 (fi) | 1993-11-05 |
| NO306048B1 (no) | 1999-09-13 |
| EP0512916B1 (en) | 1999-02-03 |
| KR100300772B1 (ko) | 2001-10-22 |
| JPH06507417A (ja) | 1994-08-25 |
| MX9202131A (es) | 1993-04-01 |
| AU2027392A (en) | 1992-12-21 |
| NO934016D0 (no) | 1993-11-05 |
| WO1992019243A1 (en) | 1992-11-12 |
| IE921461A1 (en) | 1992-11-18 |
| DK0512916T3 (da) | 1999-09-20 |
| EP0512916A2 (en) | 1992-11-11 |
| CA2108788A1 (en) | 1992-11-12 |
| CA2108788C (en) | 2003-09-30 |
| FI934913A7 (fi) | 1993-11-05 |
| NO934016L (no) | 1993-11-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2128343T3 (es) | Formulaciones de prostaglandina liposomica. | |
| MX9301634A (es) | Quinuclidinas peptidicas. | |
| MX9204132A (es) | Composiciones farmaceuticas que contienen rifaximin y procedimiento para su preparacion. | |
| ES2191286T3 (es) | Moleculas pequeñas, utiles en el tratamiento de enfermedades inflamatorias. | |
| ES2065691T3 (es) | Derivados de quinuclidina. | |
| ES2179040T3 (es) | Utilizacion de 5-fluoro-2'-desoxi-3'-tiacitidina para el tratamiento de la hepatitis b. | |
| ECSP941122A (es) | Derivados de 5-arilindoles | |
| NO884174D0 (no) | Framgangsmaate for fremstilling av terapeutisk aktive tricykliske amidinoderivater. | |
| DK10488A (da) | Benzen-derivater med antiinflammatorisk virkning og fremgangsmaade til fremstilling deraf | |
| MX9300399A (es) | Derivados heterotriciclicos. | |
| ES2166900T3 (es) | Derivados de ara-c. | |
| ES2171553T3 (es) | Derivados de quinoxalina utiles en terapia. | |
| FI892684A0 (fi) | Menetelmä terapeuttisesti aktiivisten 4-okso-imidatso/1,5-a/kinoksaliinijohdannaisten valmistamiseksi | |
| HK43186A (en) | Biologically active mixtures and salts of heterocyclic compounds | |
| ES2148600T3 (es) | Derivados de indol sustituidos. | |
| NO913187D0 (no) | Fremgangsmaate for fremstilling av terapeutisk aktive tricykliske derivater. | |
| MX9302578A (es) | Agentes antivirales. | |
| CO4180473A1 (es) | Derivados tiazoles como novedosos compuestos antivirales | |
| ITMI911577A1 (it) | Procedimento per la preparazione dell'acido 9-fluoro-10- (4-metil-1-piperazinil)-7-oxo-2, 3-diidro-7h-pirido (1, 2, 3-de) (1, 4)benzotiadin-6-carbossilico cloridrato. | |
| MX9301979A (es) | Derivados de hidrazina de los 3,4-dihidro-2h-1-benzopiranos. | |
| ES2088162T3 (es) | Tienopirazina-2,3-dionas utiles para el tratamiento de enfermedades del sistema nervioso central, y su preparacion. | |
| ES2167942T3 (es) | Empleo de 2-aminotetralinas 6,7-sustituidas apropiadas para la preparacion de una composicion farmaceutica para el tratamiento terapeutico de patologias inflamatorias y/o autoinmunes. | |
| ES2079185T3 (es) | Isoindoles con actividad cardiovascular. | |
| FI882383L (fi) | Derivat av 3-metylacylamino-5,6,7,8 -tetrahydroimidazo/1,2-a/-pyridin, deras framstaellning och anvaendning i terapi. | |
| ITMI912232A0 (it) | Derivati dell'1,2,4-triazolo farmacologicamente attivi |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG2A | Definitive protection |
Ref document number: 512916 Country of ref document: ES |